Vertex Pharma (VRTX) Tops Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
Go back to Vertex Pharma (VRTX) Tops Q1 EPS by 1c
April 27, 2017 4:01 PM EDT
-First-quarter 2017 cystic fibrosis product revenues of $481 million;
$295 million for ORKAMBI and $186 million for KALYDECO-
-Company reiterates 2017 guidance for ORKAMBI product revenues of
$1.1 to $1.3 billion and increases 2017 guidance for KALYDECO product
revenues to $710 to $730 million-
BOSTON--(BUSINESS WIRE)--
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported
consolidated financial results for the quarter ended March 31, 2017.
Vertex also reiterated guidance for total 2017 ORKAMBI®
(lumacaftor/ivacaftor) revenues and combined GAAP and non-GAAP R&D and
SG&A expenses, and increased its total 2017 guidance for KALYDECO®
(ivacaftor) revenues.
Key financial results include:
Â
Â
Three Months Ended March 31,...
More
